Indiana State Department of Health

Immunization E-Update
September 15, 2008

KINRIX

KINRIX (GlaxoSmithKline) will be available through the Indiana Vaccines for Children (VFC) Program for orders starting in October 2008. KINRIX is a new combination vaccine that contains DTaP and IPV vaccine. KINRIX may be used for the fifth dose in the DTaP immunization series and the fourth dose in the IPV series in children 4 through 6 years of age (prior to the seventh birthday) whose previous DTaP vaccine doses have been with INFANRIX and/or PEDIARIX for the first three doses and INFANRIX for the fourth dose*.

KINRIX is to be administered as a 0.5-mL dose by intramuscular injection. The preferred site of administration is the deltoid muscle of the upper arm. Do not administer this product intravenously, intradermally, or subcutaneously. It is supplied as single-dose vials containing a 0.5-mL suspension for injection The vaccine must be kept at refrigerator temperature (35°-46°F) at all times. KINRIX must never be frozen. Vaccine exposed to freezing temperature must not be used.

**KINRIX can be administered to any child 4 years through 6 years of age. ACIP recommends that whenever feasible, the same manufacturer's DTaP vaccine should be used for all doses of the series, but vaccination should not be deferred if the specific DTaP brand previously administered is unavailable or unknown. KINRIX is approved by the FDA for the 5th dose of DTaP series and the 4th dose of the IPV series ONLY. Off label use is not recommended. Use of KINRIX for any dose except the 5th dose of DTaP and the 4th dose of IPV should be considered a vaccine administration error. If KINRIX is inadvertently administered as an earlier dose in the series, the dose may be counted as valid and does not need to be repeated if the minimum age and minimum interval since the prior dose are met.*

Contraindications and precautions for KINRIX are the same as those for DTaP and IPV.

ROTARIX

ROTARIX (GlaxoSmithKline) will be available through the Indiana Vaccines for Children (VFC) Program for orders starting in October 2008. ROTARIX is a new oral vaccine for the prevention of rotavirus gastroenteritis in infants and children. ROTARIX is indicated for children 6 weeks through 32 weeks of age*.

ROTARIX vaccination series consists of two (2) - 1-mL doses administered orally beginning at 6 weeks of age at 2 and 4 months of age. Each dose should be separated by a minimum interval of at least 4 weeks. The vaccine is provided as a vial of lyophilized powder that is reconstituted with a liquid diluent in a prefilled oral applicator. **Mix only with accompanying diluent**. The vaccine must be kept at refrigerator temperature (35°-46°F) at all times. ROTARIX must never be frozen. Vaccine exposed to freezing temperature must not be used. Diluent may be stored at room temperature. ROTARIX vaccine may be administered up to 24 hours after mixing.

**ROTARIX can be administered to any child 6 weeks through 32 weeks of age. The ROTARIX package insert does indicate the labeled maximum age of any dose is 24 weeks.*

Contraindications and precautions for ROTARIX are the same as those for other rotavirus vaccines.

Provisional ACIP ROTAVIRUS recommendations for both vaccines, ROTATEQ AND ROTARIX are available @ http://www.cdc.gov/vaccines/recs/provisional/default.htm

Immunization Program
2 N. Meridian St.
Indianapolis, IN 46204

Phone: (800) 701-0704
E-mail: immunize@isdh.in.gov